Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.44 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138429 | 0.91 | MEN1 (0.50) | SMN1; SMN2MAPK1NPC1RAB9APKM | |
| SCHEMBL5138997 | 0.83 | PIM1 (0.49) | SMN1; SMN2MAPK1NPC1RAB9APKM | |
| SCHEMBL5139037 | 0.83 | MEN1 (0.39) | SMN1; SMN2NPC1RAB9AIP6K1IP6K3 | |
| SCHEMBL27648485 | 0.82 | TGFBR1 (0.53) | SMN1; SMN2NPC1RAB9APKMGRM5 | |
| SCHEMBL5200816 | 0.81 | IP6K1 (0.37) | SMN1; SMN2NPC1RAB9AIP6K1IP6K3 | |
| SCHEMBL373555 | 0.80 | TGFBR1 (0.64) | SMN1; SMN2NPC1RAB9APKMGRM5 | |
| SCHEMBL5930941 | 0.79 | TGFBR1 (0.38) | SMN1; SMN2NPC1IP6K1IP6K3IP6K2 | |
| SCHEMBL5138712 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2NPC1RAB9AIP6K1IP6K3 | |
| SCHEMBL27648467 | 0.77 | TGFBR1 (0.48) | SMN1; SMN2NPC1RAB9APKMGRM5 | |
| SCHEMBL5138504 | 0.75 | DYRK1A (0.46) | MAPK1NPC1RAB9APKMTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | SMN1; SMN2 3128/4885MAPK1 1117/4885NPC1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.